Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm).
作者信息
Rivkees Scott A
机构信息
Yale Child Health Research Center, Yale University School of Medicine, New Haven, CT 06520, USA.
出版信息
Int J Pediatr Endocrinol. 2009;2009:303509. doi: 10.1155/2009/303509. Epub 2009 Mar 4.
Abstract
摘要
相似文献
1
Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm).
Int J Pediatr Endocrinol. 2009;2009:303509. doi: 10.1155/2009/303509. Epub 2009 Mar 4.
2
Dealing with phthalates in medical devices: a case of primum non nocere (first do no harm)?
Intensive Care Med. 2016 Apr;42(4):602-604. doi: 10.1007/s00134-016-4227-5. Epub 2016 Feb 3.
3
Primum non nocere: first do no harm: reponse to Phillida Bunkle.
N Z Med J. 2018 Sep 21;131(1482):92-93.
4
A response to Primum non nocere: first do no harm.
N Z Med J. 2018 Jul 27;131(1479):91-92.
5
Primum non nocere: first do no harm.
Med Times. 1957 Jul;85(7):729-31.
6
Primum non nocere-first, do no harm with bariatric surgery.
Lancet Diabetes Endocrinol. 2021 Aug;9(8):476-477. doi: 10.1016/S2213-8587(21)00143-1. Epub 2021 Jul 1.
7
(first, to do no harm) in prostate biopsy.
Hong Kong Med J. 2019 Oct;25(5):344-345. doi: 10.12809/hkmj195088.
8
Primum non nocere - 'first do no harm'.
Perfusion. 2020 May;35(4):277. doi: 10.1177/0267659120924914.
9
"Primum non nocere"--First do no harm.
Hosp Pharm. 1976 Oct;11(10):392, 397.
10
Reply: Primum Non Nocere: First Do No Harm.
J Am Coll Cardiol. 2015 Jul 28;66(4):492-3. doi: 10.1016/j.jacc.2015.05.043.
引用本文的文献
1
Characteristics and trends in adverse drug reactions in Ghana-evidence of spontaneous reports, 2005-2021.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):657-672. doi: 10.1007/s00210-024-03302-5. Epub 2024 Jul 23.
2
Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana.
Ther Adv Drug Saf. 2022 Aug 6;13:20420986221116468. doi: 10.1177/20420986221116468. eCollection 2022.
3
Impact of an educational intervention on pharmacovigilance knowledge and attitudes among health professionals in a Nepal cancer hospital.
BMC Med Educ. 2020 Jun 3;20(1):179. doi: 10.1186/s12909-020-02084-7.
4
Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates.
J Drug Assess. 2019 Jan 5;8(1):13-20. doi: 10.1080/21556660.2019.1566137. eCollection 2019.
本文引用的文献
1
Update on the role of aromatase inhibitors in growth disorders.
Horm Res. 2009 Jan;71 Suppl 1:57-63. doi: 10.1159/000178040. Epub 2009 Jan 21.
2
Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop.
J Clin Endocrinol Metab. 2008 Nov;93(11):4210-7. doi: 10.1210/jc.2008-0509. Epub 2008 Sep 9.
3
Anaphylactic reaction to recombinant insulin-like growth factor-I.
J Pediatr Endocrinol Metab. 2008 Apr;21(4):381-4. doi: 10.1515/jpem.2008.21.4.381.
4
Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.
J Clin Endocrinol Metab. 2008 Mar;93(3):823-31. doi: 10.1210/jc.2007-1559. Epub 2007 Dec 28.
5
Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
Nat Clin Pract Oncol. 2007 Oct;4(10):591-602. doi: 10.1038/ncponc0934.
6
The role of recombinant insulin-like growth factor I in the treatment of the short child.
Curr Opin Pediatr. 2007 Aug;19(4):458-64. doi: 10.1097/MOP.0b013e3282094126.
7
Post-marketing studies of drug efficacy: why?
Am J Med. 1985 Mar;78(3):475-80. doi: 10.1016/0002-9343(85)90341-9.
Zotero 插件